Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis
Provider: View Press Release Type: Link Title: Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis | GSK Description: Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of CKD a new oral treatment option
GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations
GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations
Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
Provider: View Press Release Type: Link Title: Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis | GSK Description: GSK plans to initiate a phase II/III trial for systemic sclerosis associated interstitial lung disease (SSc-ILD) in the first half of 2023.
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
Provider: View Press Release Type: Link Title: VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain | GSK Description: SARS-CoV-2 spike protein vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the EU
GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
Provider: View Press Release Type: Link Title: GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets | GSK Description: A strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing programme
GSK announces new global headquarters in central London
Provider: View Press Release Type: Link Title: GSK announces new global headquarters in central London | GSK Description: GSK today announced that its new global headquarters will be in central London. The company will move to the new headquarters in 2024.
